Asthma
Conditions
Keywords
Asthma, Doping, Salmeterol, Beta-agonist, Urine concentrations
Brief summary
The purpose of the study is to assess the blood and urine concentrations of inhaled salmeterol.
Detailed description
The purpose of the study is to assess the serum and urine concentrations of salmeterol after inhalation of 100 microgram salmeterol in one dose. Furthermore, to evaluate any difference in three groups: 10 healthy men, 10 male asthmatic subjects and 10 male elite athletes with asthma.
Interventions
DRUGinhaled salmeterol
Inhalation of 100 micrograms salmeterol in one dose.
Sponsors
Hormone Laboratory, Aker University Hospital, Oslo, Norway
Bispebjerg Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Physician-diagnosed asthma with positive reversibility or challenge test. * Informed consent. * Age between 18-45 years. * Sex: male. * Asthma classified as mild to moderate according to GINA guidelines. * Used beta-2-agonist in minimum 12 months.
Exclusion criteria
* Smokers or ex-smokers with a smoking history of 10 pack years or more. * Respiratory tract infections within the last 2 weeks prior to study day. * Subjects with other chronic diseases than asthma and/or allergy. * Allergy towards the study medicine. * Use of beta-2-agonist 10 days prior to study day.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum and urine concentrations of salmeterol | baseline, 4, 8, and 12 hours after medicine administration |
Countries
Denmark
Contacts
Primary ContactJimmi Elers, MD
Outcome results
None listed